[1] Hyuna S ,Jacques F ,Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. [J]. CA: A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. [J]. Lancet,2022, 400(10360):1345-1362.
[3] Eun J W, Yoon J H, Ahn H R, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. [J]. Cancer Commun (Lond),2023,43(4):455-479.
[4] Kerr S ,Kerr D. Novel treatments for hepatocellular cancer. [J].Cancer Letters,2009, 286(1):114-120.
[5] Kudo M, Finn R S, Galle P R, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with barcelona clinic liver cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase Ⅲ study. [J]. Liver Cancer, 2022,12(3):238-250.
[6] Cheng A L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.[J]. J Hepatol, 2022,76(4):862-873.
[7] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.[J]. Lancet, 2017,389(10088):2492-2502.
[8] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. [J]. Lancet Oncol, 2021,22(7):977-990.
[9] Scheiner B, Kang B, Balcar L, et al. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy[J]. Hepatology,2025,81(6):1714-1727.
[10] Wang S J, Dougan S K, Dougan M, et al. Immune mechanisms of toxicity from checkpoint inhibitors[J]. Trends Cancer,2023,9(7):543-553.
[11] Sun L, Bleiberg B, Hwang W T, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer[J]. JAMA Oncol,2023,9(8):1075-1082.
[12] Robert C, Marabelle A, Herrscher H, et al. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm[J]. Nat Rev Clin Oncol, 2020,17(11):707-715.
[13] Llovet J M, Lencioni R. mRECIST for HCC: performance and novel refinements[J]. J Hepatol,2020,72(2):288-306.
[14] Kim D J, Clark P J, Heimbach J, et al. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size[J]. Am J Transplant,2014,14(6):1383-1390.
[15] Choi M H, Park G E, Oh S N, et al. Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization[J]. Acad Radiol,2018,25(11):1363-1373.
[16] Shen Y C, Liu T H, Nicholas A, et al. Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab[J]. J Clin Oncol, 2024,42(34):4060-4070.
[17] Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment[J]. Int Immunopharmacol,2024,143(Pt 2):113365.
[18] Carlino M S, Larkin J, Long G V, et al. Immune checkpoint inhibitors in melanoma[J]. Lancet,2021,398(10304):1002-1014.
[19] Chiang C L, Chan K S K, Chiu K W H, et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma[J]. JAMA Oncol, 2024,10(11):1548-1553. |
